Radiopharmaceuticals Market 2021, Industry Size, Share, Business Growth Opportunities, Analysis, Competitive Landscape, Regional Forecast to 2025
Research Reports
Jan 08, 2021
Radiopharmaceuticals Market Overview
Market Research Future (MRFR) has announced a new research report on the global radiopharmaceuticals market. The report estimates the global radiopharmaceuticals market is expected to register a CAGR of 8.10% to reach USD 15,060.87 Million by 2025 forecast period due to the growing demand for radiopharmaceuticals in diagnostic as well as therapeutic applications in the healthcare sector. The report takes into account the historical trajectory of the radiopharmaceuticals market, using past statistics of the market to construct a valid platform for future projections. The segmentation hierarchy within the global radiopharmaceuticals market is also explained in detail in the report, along with information on the competitive landscape of the market and the leading players operating in it.
Get customized Sample with complete Toc, Inclusive of COVID-19 Industry Analysis @ https://www.marketresearchfuture.com/sample_request/1650
Radiopharmaceuticals are a part of nuclear medicine and are used for diagnosis as well as treatment of a number of diseases. Radioisotopes that emit long-range gamma rays are mostly used in diagnostic applications, as the radiation needs to escape the body before being detected by the diagnostic instrument. In a similar manner as X-rays, these radioisotopes help physicians diagnose a number of diseases. In contrast, radioisotopes that emit short-range particles such as alpha and beta particles are used in therapeutic applications, as short-range particles “burn up”, i.e. lose their energy, over relatively short distances, allowing spectacular results in terms of cell destruction on a highly local scale. Radioisotopes of the latter kind also stay for longer periods of time in the human body, allowing for prolonged treatment.
The growing prevalence of cancer is the primary driver for the global radiopharmaceuticals market, as cancer treatment accounts for the majority of the application of radiopharmaceuticals in the healthcare sector. Growing investment in cancer research in a number of countries round the world is likely to remain a major driver for the radiopharmaceuticals market over the forecast period, as many countries have started to take the threat of cancer seriously following a steady rise in the prevalence of many cancer types. On the other hand, the high cost of radiopharmaceuticals and the risks of using radiopharmaceuticals in therapeutic applications are likely to hamper the growth prospects of the global radiopharmaceuticals market over the forecast period.
Radiopharmaceuticals Market Segmentation Analysis:
The global radiopharmaceutical market is segmented based on type, type of test, application, route of administration, end user, and region.
By type, the market for radiopharmaceuticals is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. The diagnostics segment is further sub-segmented into SPECT radiopharmaceuticals and PET radiopharmaceuticals; the SPECT radiopharmaceuticals segment is further sub-segmented into technetium-99m, thallium-201, iodine-123, and others, while The PET radiopharmaceuticals segment is further sub-segmented into F-18, rubidium-82, and others. The therapeutic radiopharmaceuticals segment is further sub-segmented into beta emitters, alpha emitters, and brachytherapy. The beta emitters segment is further sub-segmented into iodine-131, yttrium-90, samarium-153, rhenium-186, lutetium-177, and others. The brachytherapy segment is sub-segmented into iodine-125, iridium-192, cesium-131, and others.
By type of test, the market is segmented into myocardial perfusion scan, lung scan, bone scan, white blood cell scan, gallium scan, renal nuclear medicine scan, parathyroid scans, hepatobiliary scans, cerebral perfusion scan, and others. The myocardial perfusion scan segment is further sub-segmented into technetium-99m, thallium-201, rubidium-82, and others. The lung scan segment is further sub-segmented into xenon-133, krypton-81m, and others. The bone scan segment is further sub-segmented into technetium-99m, fluoride-18, and others. The white blood cell scan segment is sub-segmented into indium-111 and others.
By application, the market is segmented into oncology, cardiology, neurology, urology, and others. The oncology segment is further segmented into prostate cancer, bone cancer, breast cancer, and others. The cardiology segment is further segmented into coronary artery disease, cardiomyopathy, and others. The neurology segment is further segmented into traumatic brain injury, stroke, Alzheimer’s disease, and others. The urology segment is sub-segmented into acute pyelonephritis, congenital renal anomalies, and others.
By route of administration, the market is segmented into oral, intravenous, and others.
By end user, the market is segmented into hospitals, diagnostic centers, research institutes, and others.
Radiopharmaceuticals Market Regional Analysis:
The global radiopharmaceuticals market is segmented by geography into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is the dominant regional segment of the global radiopharmaceuticals market and is likely to remain the leading contributor to the global market due to the high prevalence of cancer as well as other neurological and cardiovascular diseases in which radiopharmaceuticals are used in some capacity. The increasing investment in cancer research in the Americas, particularly the U.S., is likely to be a major driver for the radiopharmaceuticals market in the region over the forecast period.
Moreover, Asia Pacific is likely to be the fastest growing regional market due to the growing prevalence of cancer and the growing awareness about SPECT and PET systems.
Radiopharmaceuticals Market Competitive Analysis:
Leading players in the global radiopharmaceuticals market include Jubilant Life Sciences Ltd., Sun Pharmaceutical Industries Ltd., Cardinal Health Inc., GE Healthcare, Advanced Accelerator Applications SA (owned by Novartis), Nordion Inc., Bracco Diagnostic Inc., Avid Radiopharmaceuticals, IBA Dosimetry GmbH, Canadian Nuclear Laboratories, Mallinckrodt Pharmaceuticals, Lantheus Medical Imaging Inc., Medtronic, Bayer AG, and Siemens AG.
Radiopharmaceuticals Industry Updates:
In Q3 2018, Novartis (Advanced Accelerator Applications) acquired two new radioisotope drugs – Lu-PSMA-617 from Endocyte and FF-10158 from Fujifilm Toyama Chemical.
Get Premium Research Report, Inclusive of COVID-19 Impact Analysis, Find more information @ https://www.marketresearchfuture.com/reports/radio-pharmaceutical-market-1650
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
Tags:
, Reportedtimes, iCN Internal Distribution, Research Newswire, English